H E A L T H I N S I G H T S
Exciting innovation is still happening in those spaces. Startups are tackling issues like menopause and perimenopause, maternal health, pregnancy risk analysis and fertility.
Now we’ re in a new stage.
New clinical research is driving awareness of how deeply interconnected women’ s health is to the rest of healthcare. We’ re learning more about the causes and biological drivers behind conditions that affect women differently and disproportionately. If gaps in care are causing women’ s health outcomes to be worse, or if major diseases are predominantly affecting women, then those are women’ s health issues, even if women aren’ t exclusively affected.
Increased awareness has brought increased growth. Investment in women’ s health has more than tripled since 2020, creating new segments for personalised medicine. Startups are finding that serving historically underserved or disadvantaged populations in healthcare can boost the bottom line, aid in retention and play a vital role in improving and maintaining patient health. With all that upside, women’ s health startups face a difficult climate.
In the depressed markets of the last few years, no one was expected to find exits. In 2025, the pressure to exit is getting stronger and investors are increasingly apprehensive about funding late-stage companies with no exit in sight. Similar companies with initial public offerings( IPOs) in 2021 and 2022 are showing performances that don’ t make anyone eager to test the waters. M & A is more common than IPOs, but activity there is slowing too. As investments and attention to the space continue to develop, it could be a dangerous mistake to underestimate the value in women’ s health. �
www. intelligenthealth. tech 19